KRAS and neoplasm: The patients with wild-type K-ras tumor had better ORR and DCR than that of patients with mutated K-ras tumor, i.e., DCR, 60% vs. 26% (χ2 = 23.582, p<0.05), ORR, 42% vs. 11% (χ2 = 24.669, p<0.05, Table 2), indicating that detection of K-ras mutation can predict the response of the patients to cetuximab plus chemotherapy.